ZIVO Bioscience to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
June 02 2021 - 9:30AM
ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D
company engaged in the development and commercialization of
therapeutic, medicinal and nutritional bioproduct candidates
originally derived from proprietary algal cultures, today announced
that President & Chief Executive Officer Andrew Dahl will
present a corporate overview at the three-day LD Micro Virtual
Invitational Conference being held on June 8 – 10, 2021.
Mr. Dahl will deliver his corporate presentation
on June 9 at 6:00pm ET, Track 3.
Investors can register to watch the presentation
here.
Investors interested in scheduling a meeting
with management should contact assistant@ldmicro.com.
About ZIVO Bioscience, Inc.ZIVO
Bioscience, Inc. (NASDAQ: ZIVO) is a Michigan-based biotech/agtech
company dedicated to harnessing the immune health and nutritional
benefits of bioactive compounds derived from its proprietary algal
cultures. The development pipeline includes natural products
for use as dietary supplements and functional food ingredients, as
well as innovative, biologically derived and synthesized
candidates designed to deliver medicinal and pharmaceutical
benefits for humans and animals, with a specific focus on
modulating the immune and inflammatory response. Visit
www.zivobioscience.com to learn more.
Forward Looking
StatementsExcept for any historical information, the
matters discussed in this press release contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of
1934.Forward-looking statements may include statements regarding
the timing and extent of product launch and commercialization of
our products, business strategy, market size, potential growth
opportunities, plans for product applications and product
development, including the potential for ZIVO's product candidate
to be a viable alternative growth promoter in healthy birds and the
potential for reduction of pathogenic contamination of poultry
products entering the human food supply, future operations, future
efficiencies, and other financial and operating information.
Although ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that our products may not be ready for commercialization in a
timely manner or at all; risks that our products will not perform
as expected based on results of our pre-clinical and clinical
trials; our ability to raise additional funds; uncertainties
inherent in the development process of our products; changes in
regulatory requirements or decisions of regulatory authorities; the
size and growth potential of the markets for our products; the
results of clinical trials, our ability to protect our intellectual
property rights and other risks, uncertainties and assumptions,
including those described under the heading "Risk Factors" in our
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release and ZIVO undertakes no obligation to revise or update any
forward-looking statements for any reason, even if new information
becomes available in the future.
Contact:Investor Relations(248)
452 9866 ext 150ZIVO Bioscience,
Inc.Investor@zivobioscience.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Apr 2023 to Apr 2024